Loading...
21 casirivimab/imdevimab COVID-19 controlled studies, 9 RCTs
57% improvement
for early treatment, RR
0.43
[0.27-0.68]
https://c19regn.com/meta.html
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Regeneron (RCT)
38%
0.62 [0.29-1.33]
recov. time
92 (n)
91 (n)
Improvement, RR [CI]
Treatment
Control
Regeneron (RCT)
54%
0.46 [0.19-1.13]
recov. time
92 (n)
91 (n)
Regeneron (RCT)
71%
0.29 [0.17-0.48]
death/hosp.
18/1,355
62/1,341
Regeneron (RCT)
70%
0.30 [0.13-0.68]
death/hosp.
7/736
24/748
Regeneron (RCT)
29%
0.71 [0.60-0.85]
recov. time
1,355 (n)
1,341 (n)
Regeneron (RCT)
29%
0.71 [0.60-0.85]
recov. time
736 (n)
748 (n)
Weinreich (RCT)
50%
0.50 [0.09-2.72]
death
2/2,091
4/2,089
Weinreich (RCT)
67%
0.33 [0.03-3.17]
death
1/1,355
3/1,341
Weinreich (RCT)
-2%
1.02 [0.06-16.2]
death
1/736
1/748
Weinreich (RCT)
71%
0.29 [0.17-0.48]
death/hosp.
18/1,355
62/1,341
Weinreich (RCT)
70%
0.30 [0.13-0.68]
death/hosp.
7/736
24/748
Weinreich (RCT)
29%
0.71 [0.58-0.87]
recov. time
1,355 (n)
1,341 (n)
Weinreich (RCT)
29%
0.71 [0.58-0.87]
recov. time
736 (n)
748 (n)
Webb
98%
0.02 [0.00-0.27]
death
0/115
57/5,536
Webb
91%
0.09 [0.01-0.63]
hosp.
1/115
538/5,536
Cooper
77%
0.23 [0.03-1.65]
death
1/1,148
33/8,534
Cooper
48%
0.52 [0.23-1.20]
ICU
6/1,148
85/8,534
Cooper
52%
0.48 [0.35-0.64]
hosp.
45/1,148
703/8,534
Kakinoki
58%
0.42 [0.17-0.92]
progression
13/55
22/53
Komagamine
77%
0.23 [0.01-4.63]
ventilation
0/53
2/75
Komagamine
92%
0.08 [0.00-1.32]
ICU
0/53
7/75
Komagamine
68%
0.32 [0.13-0.68]
progression
8/53
33/75
Komagamine
29%
0.71 [0.58-0.87]
hosp. time
53 (n)
75 (n)
Suzuki (PSM)
-200%
3.00 [0.12-73.3]
death
1/222
0/222
Suzuki
60%
0.40 [0.05-3.45]
death
1/314
5/635
Suzuki (PSM)
45%
0.55 [0.31-0.96]
progression
17/222
31/222
Suzuki
50%
0.50 [0.31-0.80]
progression
34/314
70/365
O'Brien (DB RCT)
85%
0.15 [0.01-2.78]
hosp.
0/100
3/104
O'Brien (DB RCT)
92%
0.08 [0.00-1.37]
hosp./ER
0/100
6/104
O'Brien (DB RCT)
33%
0.67 [0.43-0.98]
symp. case
29/100
44/104
O'Brien (DB RCT)
40%
0.60 [0.45-0.81]
viral load
100 (n)
104 (n)
Shopen
-46%
1.46 [0.73-2.67]
severe case
24/116
26/243
Osugi
24%
0.76 [0.23-2.49]
hosp.
4/30
15/74
Wei
61%
0.39 [0.26-0.60]
death/hosp.
23/1,116
27/5,291
Wei
61%
0.39 [0.30-0.51]
hosp.
59/3,280
75/16,284
Wilden
82%
0.18 [0.05-0.50]
hosp.
n/a
n/a
Faraone
92%
0.08 [0.00-1.24]
death
0/11
8/23
Faraone
94%
0.06 [0.00-0.76]
oxygen
0/11
15/23
Miyashita
33%
0.67 [0.11-3.97]
ventilation
2/461
3/461
Miyashita
46%
0.54 [0.35-0.82]
oxygen
30/461
56/461
Horby (RCT)
6%
0.94 [0.86-1.02]
death
943/4,839
1,029/4,946
Horby (RCT)
-1%
1.01 [0.90-1.14]
ventilation
484/4,556
488/4,642
Horby (RCT)
21%
0.79 [0.69-0.91]
death
396/1,633
452/1,520
Horby (RCT)
13%
0.87 [0.73-1.05]
ventilation
190/1,599
202/1,484
Somersa.. (DB RCT)
36%
0.64 [0.44-0.93]
death
59/804
45/393
Somersa.. (DB RCT)
56%
0.44 [0.26-0.76]
death
24/360
24/160
Somersa.. (DB RCT)
21%
0.79 [0.44-1.40]
death
26/369
18/201
Somersa.. (DB RCT)
31%
0.69 [0.50-0.95]
death/int.
82/804
58/393
Somersa.. (DB RCT)
29%
0.71 [0.53-0.96]
no disch.
92/804
63/393
McCreary (PSM)
93%
0.07 [0.01-0.51]
death
1/652
29/1,304
McCreary (PSM)
56%
0.44 [0.28-0.68]
death/hosp.
22/652
101/1,304
McCreary (PSM)
48%
0.52 [0.33-0.82]
hosp.
22/652
85/1,304
McCreary (PSM)
40%
0.60 [0.43-0.85]
hosp./ER
40/652
133/1,304
Regeneron (RCT)
94%
0.06 [0.00-1.10]
symp. case
0/186
8/223
Regeneron (RCT)
48%
0.52 [0.25-1.07]
cases
10/186
23/223
Regeneron (DB RCT)
92%
0.08 [0.00-1.36]
hosp.
0/841
6/842
Regeneron (DB RCT)
81%
0.19 [0.12-0.30]
cases
20/841
108/842
Regeneron (DB RCT)
82%
0.18 [0.08-0.41]
cases
7/841
38/842
Regeneron (DB RCT)
89%
0.11 [0.01-2.06]
hosp./ER
0/753
4/752
Regeneron (DB RCT)
81%
0.19 [0.10-0.35]
symp. case
11/753
59/752
Regeneron (DB RCT)
62%
0.38 [0.23-0.61]
recov. time
753 (n)
752 (n)
Regeneron (DB RCT)
69%
0.31 [0.17-0.55]
viral time
753 (n)
752 (n)
Isa (DB RCT)
93%
0.07 [0.01-0.28]
symp. case
3/729
13/240
Isa (DB RCT)
93%
0.07 [0.01-0.28]
cases
0/729
10/240
casirivimab/imdevimab COVID-19 outcomes
c19regn.com Jun 2022
Favors casirivimab/im..
Favors control
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation.
FLCCC and
WCH
provide treatment protocols.
Submit